These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23581649)

  • 1. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
    Kim GH; Levy A; Compoginis G
    J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib-induced neutrophilic panniculitis.
    Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
    Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
    Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panniculitis in patients treated with BRAF inhibitors: a case series.
    Choy B; Chou S; Anforth R; Fernández-Peñas P
    Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma.
    Clarke M; Ortel B; Brockstein B; Rojanapremsuk T; Victor T; Thomas A; Cibull T
    J Cutan Pathol; 2013 Oct; 40(10):884-6. PubMed ID: 23924408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
    Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
    Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
    Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
    J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
    [No Abstract]   [Full Text] [Related]  

  • 10. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
    West ES; Williams VL; Morelli JG
    Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 12. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
    Pattanaprichakul P; Tetzlaff MT; Lapolla WJ; Torres-Cabala CA; Duvic M; Prieto VG; Tsai KY; Curry JL
    J Cutan Pathol; 2014 Mar; 41(3):326-8. PubMed ID: 24372055
    [No Abstract]   [Full Text] [Related]  

  • 16. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
    Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
    [No Abstract]   [Full Text] [Related]  

  • 17. BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.
    Broski SM; Moran EK; Glazebrook KN; Nathan MA
    Clin Nucl Med; 2016 Mar; 41(3):e149-51. PubMed ID: 26447389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
    Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
    Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.